Nilemdo (Bempedoic Acid)

Bempedoic acid, the active ingredient in Nilemdo, is an ATP citrate lyase inhibitor presented as an oral dosage form for oral use. It is prescribed as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease.

GNH USA supplies Nilemdo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory‑compliant distribution across multiple markets.

Nilemdo is used to lower low‑density lipoprotein cholesterol in patients with specific lipid disorders.

- Heterozygous familial hypercholesterolemia (HeFH): reduces LDL‑cholesterol when added to diet and maximally tolerated statin therapy. - Established atherosclerotic cardiovascular disease (ASCVD): lowers LDL‑cholesterol as an adjunct to statins, helping to reduce cardiovascular risk. - Patients unable to achieve LDL‑C targets with statins alone: provides additional LDL‑cholesterol reduction to reach guideline‑recommended levels.

The safety profile of Nilemdo includes both frequent and infrequent adverse reactions.

Common Side Effects: - Upper respiratory tract infection: mild symptoms such as sore throat or nasal congestion. - Muscle pain (myalgia): aching or soreness without severe weakness. - Elevated liver enzymes: increase in ALT or AST observed in laboratory tests. - Gastrointestinal discomfort: abdominal pain, constipation or diarrhea.

Serious or Rare Side Effects: - Tendon rupture: sudden tendon break, often in the Achilles. - Severe liver injury: marked elevation of liver enzymes with jaundice. - Hypersensitivity reactions: rash, angioedema, or anaphylaxis.

Before initiating Nilemdo, clinicians should consider several precautionary measures to ensure safe use.

- Liver function assessment: evaluate baseline ALT/AST and monitor periodically. - Uric acid monitoring: check serum uric acid levels, especially in patients with gout history. - Renal function evaluation: adjust use in severe renal impairment as recommended. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk, as safety data are limited. - Drug interaction review: assess concomitant statin dose to mitigate myopathy risk. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Nilemdo may interact with other medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - High‑dose simvastatin (>20 mg): co‑administration increases risk of myopathy and rhabdomyolysis. - Bile acid sequestrants (e.g., cholestyramine): may reduce bempedoic acid absorption, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Ezetimibe: combined lipid‑lowering effect may enhance LDL‑C reduction; monitor liver enzymes. - Fibrates (gemfibrozil, fenofibrate): potential additive effect on muscle toxicity; observe for myalgia. - Warfarin: bempedoic acid may affect INR; check coagulation parameters regularly.